Plavix patent war getting fiercer

Published: 2008-01-18 06:58:00

Updated: 2008-01-18 06:58:00

A paten war, ignited by Korean pharmaceutical firms, is getting fiercer as Sanofi-Aventis Korea unveiled its plan to defend its original Plavix patent with all possible legal means on January 15.

Experts cite growing demand for Plavix (clopidogrel bisulfate) and intensifying competition among ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK